Investors

/Investors
Investors 2019-08-02T09:20:37+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.51
-0.05 (-1.95%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :103,506
Date :11-14-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

November 14th, 2019|Comments Off on Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review [...]

Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

November 12th, 2019|Comments Off on Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

Achieves primary endpoint with statistically significant reduction in A1C versus placebo Excellent safety profile Conference call today at 8:30 a.m. ET to review Phase IIb data; Extended review event and conference call scheduled for November [...]

Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

September 18th, 2019|Comments Off on Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive [...]

Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

September 17th, 2019|Comments Off on Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the [...]